Adenosine 5'-carboxamide, also known as N6-carboxamidoadenosine, is a synthetic nucleoside analog that has been studied for its potential therapeutic effects. It is synthesized through a chemical reaction involving adenosine and a carboxamide group. Research has shown that adenosine 5'-carboxamide exhibits various pharmacological activities, including anti-inflammatory, neuroprotective, and cardioprotective effects. It is believed to exert its effects through interactions with adenosine receptors, particularly the A2A receptor. The compound's importance lies in its potential to treat a range of diseases, such as inflammatory bowel disease, Parkinson's disease, and heart failure. Studies on adenosine 5'-carboxamide are ongoing to further investigate its therapeutic potential, determine optimal dosages, and explore its safety and efficacy in human trials.'
adenosine 5'-carboxamide: structure
ID Source | ID |
---|---|
PubMed CID | 97692 |
CHEMBL ID | 4778617 |
SCHEMBL ID | 13889874 |
MeSH ID | M0069496 |
Synonym |
---|
brn 0627741 |
nsc 144697 |
beta-d-1-(6-amino-9h-purin-9-yl)-1-deoxyribofuranuronamide |
ribofuranuronamide, 1-(6-amino-9h-purin-9-yl)-1-deoxy-, beta-d- |
adenosine 5'-carboxamide |
beta-d-ribofuranuronamide, 1-(6-amino-9h-purin-9-yl)-1-deoxy- |
PDSP2_000985 |
35788-21-7 |
PDSP1_001001 |
adenosine 5'-carboxylic acid amide |
SCHEMBL13889874 |
1-(6-amino-9h-purin-9-yl)-1-deoxy-beta-d-ribofuranuronamide |
DTXSID401202089 |
nww , |
(2~{s},3~{s},4~{r},5~{r})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolane-2-carboxamide |
bdbm50552889 |
chembl4778617 , |
Pathway | Proteins | Compounds |
---|---|---|
S-methyl-5'-thioadenosine degradation I | 4 | 17 |
L-methionine salvage cycle I (bacteria and plants) | 19 | 38 |
L-methionine salvage cycle II (plants) | 8 | 32 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Heat shock protein HSP 90-alpha | Homo sapiens (human) | Ki | 3.0000 | 0.0002 | 0.5415 | 2.7000 | AID1694547 |
Endoplasmin | Homo sapiens (human) | Ki | 7.0000 | 0.0040 | 1.3205 | 7.0000 | AID1694546 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Heat shock protein HSP 90-alpha | Homo sapiens (human) | Kd | 50.0000 | 0.0003 | 0.9488 | 9.8000 | AID1694547 |
Endoplasmin | Homo sapiens (human) | Kd | 34.0000 | 0.2000 | 1.9390 | 8.6000 | AID1694546 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1694546 | Displacement of FITC-geldanamycin from GRP94 (unknown origin) after 24 hrs by fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3 | Biological Evaluation of 5'-( |
AID1694547 | Displacement of FITC-geldanamycin from HSP90alpha (unknown origin) after 24 hrs by fluorescence polarization assay | 2021 | ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3 | Biological Evaluation of 5'-( |
AID1694549 | Displacement of FITC-geldanamycin from HSP90alpha (unknown origin) at 50 uM after 24 hrs by fluorescence polarization assay relative to control | 2021 | ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3 | Biological Evaluation of 5'-( |
AID1694550 | Selectivity index, ratio of Kd for displacement of FITC-geldanamycin from GRP94 (unknown origin) after 24 hrs by fluorescence polarization assay to Kd for displacement of FITC-geldanamycin from HSP90alpha (unknown origin) after 24 hrs by fluorescence pola | 2021 | ACS medicinal chemistry letters, Mar-11, Volume: 12, Issue:3 | Biological Evaluation of 5'-( |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.07) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |